Jyong Biotech (MENS) Competitors $7.86 +0.05 (+0.64%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MENS vs. GMTX, ARWR, APLS, NAMS, TWST, DNLI, KNSA, AGIO, RXRX, and CGONShould you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), Recursion Pharmaceuticals (RXRX), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Jyong Biotech vs. Its Competitors Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals NewAmsterdam Pharma Twist Bioscience Denali Therapeutics Kiniksa Pharmaceuticals International Agios Pharmaceuticals Recursion Pharmaceuticals CG Oncology Gemini Therapeutics (NASDAQ:GMTX) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Is GMTX or MENS more profitable? Jyong Biotech's return on equity of 0.00% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Jyong Biotech N/A N/A N/A Do insiders & institutionals have more ownership in GMTX or MENS? 75.4% of Gemini Therapeutics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, GMTX or MENS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-53.38Jyong BiotechN/AN/AN/AN/AN/A Does the media favor GMTX or MENS? In the previous week, Gemini Therapeutics' average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score. Company Overall Sentiment Gemini Therapeutics Neutral Jyong Biotech Neutral SummaryGemini Therapeutics and Jyong Biotech tied by winning 2 of the 4 factors compared between the two stocks. Get Jyong Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MENS vs. The Competition Export to ExcelMetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$593.78M$780.02M$2.18B$8.95BDividend YieldN/A4.84%2.67%4.06%P/E RatioN/A1.0922.3220.10Price / SalesN/A230.5295.22120.29Price / CashN/A23.4413.8857.86Price / BookN/A6.13108.905.56Net IncomeN/A-$27.85M-$142.13M$248.40M7 Day Performance-18.30%0.67%0.56%4.67%1 Month PerformanceN/A8.48%2.22%6.64%1 Year PerformanceN/A6.72%22.83%21.31% Jyong Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MENSJyong BiotechN/A$7.86+0.6%N/AN/A$593.78MN/A0.0031Gap UpGMTXGemini TherapeuticsN/A$54.75+3.0%N/A+14.5%$2.37BN/A-54.7530ARWRArrowhead Pharmaceuticals3.7204 of 5 stars$16.84+0.3%$43.71+159.6%-31.4%$2.33B$3.55M-12.03400News CoverageAPLSApellis Pharmaceuticals4.4084 of 5 stars$17.42-4.6%$39.79+128.4%-51.7%$2.19B$781.37M-9.73770NAMSNewAmsterdam Pharma2.2562 of 5 stars$19.46-2.0%$42.89+120.4%+0.1%$2.18B$45.56M-10.354TWSTTwist Bioscience4.4106 of 5 stars$35.59-6.8%$50.40+41.6%-24.5%$2.13B$312.97M-10.95990News CoverageDNLIDenali Therapeutics4.5845 of 5 stars$14.25-3.0%$33.71+136.6%-32.4%$2.07B$330.53M-5.34430KNSAKiniksa Pharmaceuticals International3.2583 of 5 stars$27.95+0.3%$38.80+38.8%+37.0%$2.04B$481.17M-111.80220Analyst UpgradeAGIOAgios Pharmaceuticals3.9657 of 5 stars$35.21-2.4%$58.60+66.4%-11.9%$2.04B$36.50M3.13390RXRXRecursion Pharmaceuticals1.9086 of 5 stars$4.93-6.5%$7.00+42.0%-27.6%$2.00B$58.84M-2.79400Trending NewsAnalyst ForecastHigh Trading VolumeCGONCG Oncology2.3389 of 5 stars$26.25-2.4%$58.67+123.5%-19.0%$2.00B$662K-17.3861 Related Companies and Tools Related Companies GMTX Alternatives ARWR Alternatives APLS Alternatives NAMS Alternatives TWST Alternatives DNLI Alternatives KNSA Alternatives AGIO Alternatives RXRX Alternatives CGON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MENS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jyong Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jyong Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MENS Stock Alerts